Aclarion Inc. Shares Experience a Modest Decline Amid Broader Market Volatility
Aclarion Inc. (ticker ACON) closed its most recent trading session at a slight discount, reflecting a broader slide in the technology‑focused segment of the market. At 06:43 AM Central Europe on Thursday, 22 November, the share price was USD 1.95, a decline of 1.02 % from the previous day. With a market capitalization of USD 5.7 million and a circulating supply of 2.9 million shares, the company remains a relatively small‑cap player in the healthcare technology space.
Trading Activity and Technical Indicators
In the last 24 hours, the cumulative turnover for Aclarion stocks was USD 20.3 thousand, indicating modest liquidity relative to the company’s valuation. The 200‑day simple moving average sits at USD 2.97, suggesting that the current price is trading well below the long‑term average. Over the past year, the share has shown significant volatility: the all‑time high was USD 9.36 on 1 August 2026, while the lowest point in the same period fell to USD 1.85 on 19 October 2026.
Despite the recent dip, Aclarion’s performance over the last month has deteriorated by 25.86 %, underscoring a trend of declining investor confidence or broader sector pressure.
Peer Performance in the Same Trading Window
Aclarion’s recent performance can be contextualised by examining the movements of related stocks over the same 24‑hour period:
| Stock | Ticker | % Change | Current Price | Market Capitalisation |
|---|---|---|---|---|
| Emerson Radio | MSN | +3.12 % | USD 0.33 | USD 6.7 million |
| Mangoceuticals | MGRX | –1.67 % | USD 0.30 | USD 6.7 million |
| Enveric Biosciences | ENVB | +4.86 % | USD 1.51 | USD 6.8 million |
| Endra Life Sciences | NDRA | +4.70 % | USD 4.68 | USD 6.7 million |
| Aurora Spine | ASG.V | 0 % | CAD 0.12 | CAD 9.4 million |
While Aclarion’s share declined, several of its peers—particularly Enveric Biosciences and Endra Life Sciences—reported gains above 4 %, suggesting that sector‑specific catalysts or company‑specific news may have influenced investor sentiment.
Company Overview
Aclarion Inc. is a United States‑based healthcare technology firm that specialises in magnetic resonance spectroscopy (MRS). The company has developed a proprietary biomarker intended to optimise clinical treatments and has integrated artificial intelligence to enhance quality control processes, flagging sub‑optimal spectroscopy data in real time. This combination of advanced imaging technology and AI‑driven analytics positions Aclarion at the intersection of precision medicine and data‑centric healthcare solutions.
Outlook
Given the current market trajectory and the company’s modest capitalization, investors should monitor both technical indicators—such as the 200‑day moving average—and fundamental developments, including product pipeline progress and regulatory milestones. The recent decline, coupled with the broader peer performance, highlights the need for a careful assessment of risk and opportunity in this rapidly evolving sector.